Spyre Therapeutics reports Phase 2 SKYWAY RA data for SPY072 shows statistically significant benefit vs placebo

• Spyre Therapeutics reported topline Phase 2 SKYWAY rheumatoid arthritis sub-study results for TL1A antibody SPY072.
• Both doses delivered statistically significant benefits versus placebo on at least one key clinical outcome, supporting proof-of-mechanism in RA.
• Safety appeared comparable to placebo, reinforcing tolerability consistent with the TL1A class.
• Effect size missed Spyre’s threshold to advance SPY072 as an RA monotherapy, shifting emphasis toward other indications and combinations.
• Further topline readouts are scheduled for psoriatic arthritis and axial spondyloarthritis in Q4 2026, hidradenitis suppurativa combination in late 2027 or early 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001636282-26-000105), on August 25, 2026, and is solely responsible for the information contained therein.